Antisense oligonucleotide compositions and methods for the modulation of activating protein 1

Patent Citations (40)

Non-Patent Literature (92)

• Kemeny et al., A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin, Cancer, vol. 71, pp. 1964-1970, Mar. 1993.Applicant
• Su et al., c-fos is a positive regulator of carcinogen enhancement of adenovirus transformation, Oncogene, vol. 10(10), pp. 2037-2049, May 1995.Applicant
• Rojanasakul et al., Antisense oligonucleotide therapeutics: drug delivery and targeting, Advanced Drug Delivery Reviews, vol. 18, pp. 115-131, 1996.Applicant
• Gewirtz et al., Facilitating oligonucleotide delivery: helping antisense deliver on its promise, Proc. Natl. Acad. Sci., vol. 93, pp. 3161-3163, May 1995.Applicant
• Chen et al., Antisense oligodeoxynucleotide to c-jun inhibits proliferation of transformed NIH 3T3 cells induced by E5a of HPV-11, Cancer, vol. 85, pp. 119-123, 1994.Applicant
• Protocols for Oligonucleotide Conjugates (Methods in Molecular Biology, vol. 26) Agrawal, S., ed., Humana Press, Totowa, NJ, 1994.Applicant
• The Merck Manual of Diagnosis and Therapy, 15th Ed., pp. 1206-1228, Berkow et al., eds., Rahay, N.J., 1987.Applicant
• Angel and Herrlich, Chapter 1, and Schuermann, Chapter 2 in: The FOS and JUN Families of Proteins, Angel and Herrlich, eds., pp. 3-35, CRC Press, Boca Raton, FL, 1994.Applicant
• Molecular Biology of the Cell, Alberts et al., eds., pp. 331-332, Garland Publishing Inc., New York, 1983.Applicant
• Molecular Biology of the Cell, Alberts et al., eds., pp. 411-415 Garland Publishing Inc., New York, 1983.Applicant
• Molecular Biology of the Cell, Alberts et al., eds., Chapter 16 pp. 891-950, Garland Publishing, Inc., New York, 1983.Applicant
• Angel and Karin, “The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation”, Biochim. Biophys. Acta, 1991, 1072, 129.Applicant
• Bailly et al., “PCR-based development of DNA substrates containing modified bases: An efficient system for investigating the role of the exocyclic groups in chemical and structural recognition by minor groove binding drugs and proteins”, Proc. Natl. Acad. Sci. U.S.A., 1996, 93:13623.Applicant
• Bernhard et al., “Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells”, Proc. Natl. Acad. Sci. (U.S.A.), 1994, 91, 4293.Applicant
• Binetruy et al., “Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain”, Nature, 1991, 351, 122.Applicant
• Birkedal-Hansen, “Proteolytic remodeling of extracelllar matrix”, Current Op. Biol., 1995, 7, 728.Applicant
• Blume and Cevc, “Liposomes for the sustained drug release in vivo”, Biochem. et Biophys. Acta, 1990, 1029, 91.Applicant
• Bohmann et al., “Human Proto-Oncogene c-jun Encodes a DNA Binding Protein with Structural and Functional Properties of Transcription Factor AP-1”, Science, 1987, 238, 1386; Angel et al., Nature, 1988, 332, 166.Applicant
• Brigstock et al., “Species-Specific High Molecular Weight Forms of Basic Fibroblast Growth Factor”, Growth Factors, 1990, 4, 45.Applicant
• Chen et al. “Antisense oligodeoxynucleotide to c-jun inhibits proliferation of transformed NIH 3T3 cells induced by E5a of HPV-11”, Cancer Lett., 1994, 85, 119.Applicant
• Chonn and Cullis, “Recent advances in liposomal drug-delivery systems”, Current Op. Biotech., 1995, 6, 698.Applicant
• Cobb and Goldsmith, “How MAP Kinases Are Regulated”, J. Biol. Chem., 1995, 270, 14843.Applicant
• Crooke et al., “Pharmacokinetic Properties of Several Novel Oligonucleotide Analogs in Mice”, J. Pharmacol. Exp. Ther., 1996, 277, 923.Applicant
• Curran et al., “Isolation and characterization of the c-fos(rat) cDNA and analysis of post-translational modification in vitro”, Oncogene, 1987, 2:79.Applicant
• DeVirgilio et al., “Cloning and Disruption of a Gene Required for Growth Required for Growth on Acetate but not on Ethanol: the Acetyl-Coenzyme A Synthetase Gene of Saccharomyces cerevisiae”, Yeast, 1992, 8, 1043.Applicant
• Ettinger et al., “Intrathecal Methotrexate Overdose Without Neurotoxicity”, 1978, Cancer, 41, 1270, 1978.Applicant
• Ewel et al., “Polyinosinic-Polycytidylic Acid Complexed with Poly-L-lysine and Carboxymethylcellulose in combination with Interleukin 2 in Patients with Cancer: Clinical and Immunological Effects”, Cancer Research, 1992, 52:3005.Applicant
• Fraley et al., “New generation in liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids”, Trends Biochem. Sci., 1981, 6, 77.Applicant
• French et al., “Expression of two related nonstructural proteins of bluetongue virus (BTV) type 10 in insect cells by a recombinant bacullovirus: production of polyclonal ascitic fluid and characterization of the gene product in BTV-infected BHK cells”, J. Virol., 1989, 63, 3270.Applicant
• Gao et al., “Cloning and characteriaztion of a mouse gene with homology to the human von Hippel-Lindau Disease tumor suppressor gene: implications for the potential organization of the human von Hippel-Lindau disease gene”, Cancer Res., 1995, 55, 743.Applicant
• Gebeyehu, G., “Novel biotinylated nucleotide—analogs for labeling and colorimetric detection of DNA”, et al., Nucleic Acids Res., 1987, 158, 4513.Applicant
• Gelbert et al., “Analysis of GPT activity in mammalian cells with a chromosomally integrated shuttle vector containing altered gpt genes”, Somat. Cell. Mol. Genet., 1990, 16, 173.Applicant
• Gillardon et al., “Inhibition of c-Fos protein expression in rat spinal cord by antisense oligodeoxynucleotide superfusion”, Eur. J. Neurosci., 1994, 6, 880.Applicant
• Gillardon et al., “Expression of c-Fos and c-Jun in the cornea, lens and retina after ultraviolet irradiation of the rat eye and effects of topical antisense oligodeoxynucleotides”, British J. Ophthal., 1995, 79, 277.Applicant
• Gillardon et al., “Inhibition of c-Fos expression in the UV-irradiated epidermis by topical appliaction of antisense oligodeoxynucleotides suppresses activation of proliferating cell nuclear antigen”, Carcinogenesis, 1995, 16, 1853.Applicant
• Gold and Stormo, Chapter 78 in: Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology, vol. 2, p. 1303, Neidhardt et al., eds., American Society for Microbiology, Washington, D.C., 1987.Applicant
• Gum et al., “Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences”, J. Biol. Chem., 1996, 271, 10672.Applicant
• Hanvey et al., “Antisense and Antigene properties of peptide nucleic acids”, Science, 1992, 258:1481.Applicant
• Hattori et al., “Structure and chromosomal localization of the functional intronless human JUN protooncogene”, Proc. Natl. Acad. Sci. U.S.A., 1988, 85:9148.Applicant
• Himelstein et al., “Metalloproteinases in tumor progression: the contribution of MMP-9”, Invasion & Metastasis, 1994, 14, 246.Applicant
• Hua et al., “Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system”, Cancer Res., 1996, 56, 5279.Applicant
• Huhtala et al., “Complete structure of the human gene for 92-kDa type IV collagenase”, J. Biol. Chem., 1991, 266:16485.Applicant
• Kabanov et al., “A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells”, FEBS Lett., 1990, 259, 327.Applicant
• Kanagasundaram et al., “Isolation and characterization of the gene encoding gluconolactonase from Zymomonas mobilis”, Biochim. Biophys. Acta, 1992, 1171, 198.Applicant
• Kemeny et al., “A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin”, Cancer, 1993, 71:1964.Applicant
• Kerr et al., “Growth factors regulate transin gene expression by c-fos-dependent and c-fos independent pathways”, Science, 1988, 242, 1242.Applicant
• Kerr et al., “TGF-β1 inhibition of transin/stromelysin gene expression is mediated through a fos binding sequence”, Cell, 1990, 61, 267.Applicant
• Kornberg, A., DNA Replication, pp. 4-7, W.H. Freeman & Co., San Francisco, 1980.Applicant
• Kornberg, A., DNA Replication, pp. 75-77, W.H. Freeman & Co., San Francisco, 1980.Applicant
• Lappalainen et al., “Cationic liposomes mediated delivery of antisense oligonucleotides targeted to HPV 16 E7 mRNA in CaSki cells”, Antiviral Res., 1994, 23, 119.Applicant
• Letsinger et al., “Cholesteryl-conjugated oligonucleotides: Synthesis, properties and activity as inhibitors of replication of human immunodeficiency virus in cell culture”, Proc. Natl. Acad. Sci. USA, 1989, 86, 6553.Applicant
• Liu et al., “Suppression of Ischemia-induced fos expression and Ap-1 activity by an antisense oligodeoxynucleotide to c-fos mRNA”, Ann. Neurol., 1994, 36, 566.Applicant
• Luer and Hatton, “Vanomycin administration into the cerebrospinal fluid: a review”, The Annals of Pharmacotherapy, 1993, 27, 912.Applicant
• Mannino et al., “Liposome Mediated Gene Transfer”, Biotechniques, 1988, 6, 682.Applicant
• Manoharan et al., “Cholic acid-oligonucleotide conjugates for antisense applications”, Bioorg. Med. Chem. Let., 1994, 4, 1053.Applicant
• Manoharan et al., “Cehmical modifications to improve upake and bioavailability of Antisense oligonucleotides”, Antisense Strategies, Ann. N.Y. Acad. Sci., 1992, 660, 306.Applicant
• Manoharan et al., “Oligonucleotide conjugates: Alteration of the pharmacokinetic properties of antisense agents” Nucleosides & Nucleotides, 1995, 14, 969.Applicant
• Manoharan et al., “Lipidic Nucleic Acids”, Tetrahedron Lett., 1995, 36, 3651.Applicant
• Manoharan et al., “Introduction of a lipophilic thioether tether in the minor groove of nucleic acids for antisense applications”, Bioorg. Med. Chem. Let., 1993, 3, 2765.Applicant
• Markussen et al., “Translational control of oskar generates Short OSK, the isoform that induces pole plasm assembly”, Development, 1995, 121, 3723.Applicant
• Martin et al., “A new access to 2'-O-alkylated ribonucleosides and properties of 2'-O-alkylated oligoribonucleotides”, Helv. Chim. Acta, 1995, 78, 486.Applicant
• McDermott et al., “Structure and lens expression of the gene encldoing chicken βA3/A1-crystallin”, Gene. 1992, 117, 193.Applicant
• Mishra et al., “Improved leishmanicidal effect of phosphorothioate antisense oligonucleotides by LDL-mediated delivery”, Biochim. Biophys. Acta, 1995, 1264, 229.Applicant
• Monaco et al., “Structure of two rat genes coding for closely related rolipram-sensitive cAMP phosphodiesterases”, J. Biol. Chem., 1994, 269, 347.Applicant
• Morishita et al., “Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia”, Proc. Natl. Acad. Sci. (U.S.A.), 1993, 90, 8474.Applicant
• Nielsen et al., “Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide”, Science, 1991, 254, 1497.Applicant
• Oberhauser et al., “Effective incorporation of 2'-O-methyl-oligoribonucleotides into liposomes and enhanced cell association through modification with thiocholesterol”, Nucl. Acids. Res., 1992, 20, 533.Applicant
• Olsen et al., “Inhibition of protein kinase-A by overexpression of the cloned human protein kinase inhibitor”, Mol. Endocrinol., 1991, 5, 1246.Applicant
• Perri et al., “Interactions of plasmid-encoded replication initiation proteins with the origin of DNA replication in the broad host range plasmid RK2”, J. Biol. Chem., 1991, 266, 12536.Applicant
• Pushpa-Rekha et al., “Rat phosholipid-hydroperoxide glutathione peroxidase”, J. Biol. Chem., 1995, 270, 26993.Applicant
• Raitano et al., The bcr-abl leukemia oncogene activates jun kinase and requires jun for transformation, Proc. Natl. Acad. Sci. (USA), 1995, 92, 11746.Applicant
• Rogers et al., “Alternative splicing dictates translational start in Epstein-Barr virus transcripts”, EMBO J., 1990, 9, 2273.Applicant
• Rubenstein et al., “Antisense Oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice”, J. Surg. Oncol., 1996, 62:194.Applicant
• Ruoslahti, “How Cancer Spreads”, Sci. Amer., 1996, 275, 72.Applicant
• Ryder et al., “Induction of protooncogene c-jun by serum growth factors”, Proc. Natl. Acad. Sci. U.S.A., 1988, 85:8464.Applicant
• Sakai et al., “Structure and expression of the rat c-jun messenger RNA: tissue distribution and increase during chemical hepatocarcinogenesis”, Cancer Res., 1989, 49:5633.Applicant
• Saison-Behmoaras et al., “Short modified antisense oligonucleotides directed gainst Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation”, EMBO J., 1991, 10, 111.Applicant
• Sambrook et al., Molecular Cloning. A Laboratory Manual, vol. 2, p. 10.59, Cold Spring Harbor Laboratory Press, 1989.Applicant
• Sato et al., “Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells”, Oncogene, 1993, 8:395.Applicant
• Saul et al., “celB, a gene coding for bifunctional cellulase from the extreme thermophile ‘Caldocellum saccharolyticum’”, Appl. Environ. Microbiol., 1990, 56, 3117.Applicant
• Shaw, “Treatment of intractable cancer pain by electronically controlled parenteral infusion of analgesic drugs”, Cancer, 1993, 72(11) Suppl., 3416.Applicant
• Shea et al., “Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates”, Nucl. Acids. Res., 1990, 18, 3777.Applicant
• Smeal et al., “Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-jun on serines 63 and 73”, Nature, 1991, 354, 494.Applicant
• Soprano et al. “Use of antisense oligomers to study the role of c-jun in G1 progression”, Ann. N. Y. Acad. Sci., 1992, 660, 231.Applicant
• Stetler-Stevenson et al., “Tumor cell interactions with the extracelular matrix during invasion and metastasis”, Annu. Rev. Cell. Biol., 1993, 9, 541.Applicant
• Svinarchuk et al., “Inhibition of HIV proliferation in MT-4 cells by antiense oligonucleotide conjugated to lipophilic groups”, Biochimie, 1993, 75, 49.Applicant
• Van Beveren et al., “Analysis of FB-J-MuSV provirus and c-fos (mouse) gene reveals that viral and cellular fos gene products have different carboxy termini”, Cell, 1983, 32:1241.Applicant
• Van Straaten et al., “Complete nucleotide sequence of a human c-onc gene: deduced amino acid sequence of the human c-fos protein”, Proc. Natl. Acad. Sci. U.S.A., 1983, 80:3183.Applicant
• Whitesell et al., “Stability, clearance and disposition of intraventricularly administered oligodeoxynucleotides: Implications for therapeutic application within the central nervous system”, Proc. Natl. Acad. Sci. (USA), 1993, 90, 4665.Applicant
• Yaida et al., “Distribution of phosphodiester and phosphorothioate oligonucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization”, Regul. Pept., 1995, 59, 193.Applicant
• Yaoita et al., “Xenopus laevis α and β thyroid hormone receptors”, Proc. Natl. Acad. Sci. USA, 1990, 87, 7090.Applicant
• Zimm et al., “Cerbrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone”, Cancer Research, 1984, 44, 1698.Applicant